Allozymes, a Singapore-based innovator in enzyme discovery and engineering, has on Monday announced the closing of a $15 million Series A funding round led by Seventure Partners of France and Xora Innovation of Singapore.

Allozymes said in a statement that new investors include NUS Technology Holdings and Thia Ventures also participated the funding round.

Meanwhile, SOSV, and Entrepreneur First, continued their investment in the company in this round of funding.

Allozymes said the significant investment underscores the growing recognition of its transformative potential, accelerates its expansion into Europe, and forges strategic partnerships within the food and chemical industries while paving the way for new partnerships in the pharmaceutical and life science industry.

Additionally, the funding will fuel the development of the industry’s most comprehensive enzyme data library for future enzyme discovery endeavors.

Other areas the funding will be deployed in are global expansion, platform advancement, vertical expansion Co-development.

The firm said it will establish a presence in key regions to address the diverse needs of industries worldwide.

It will also build in-house strain engineering, bioprocess, and downstream processing capabilities to enable end-to-end development of new enzymes and strains.

It will also utilize Allozymes platform enzyme engineering to develop robust biosolutions for partners in the pharmaceutical and life science industry, enabling innovative products like sugar alternatives, sustainable production of high-value ingredients, bioremediation, and biosecurity.

Allozymes noted the Series A funding will further empower its development of the industry’s most comprehensive enzyme data library.

Powerful artificial intelligence (AI)/machine learning (ML) algorithms will leverage this data to enable the prediction and generation of novel, robust biocatalytic solutions for various industries, it added.

“We are thrilled to have secured this funding from a distinguished group of investors who share our vision for the transformative potential of enzymes,

“This investment is a testament to our progress in developing a truly unique and powerful enzyme engineering platform. We are committed to unlocking the full potential of enzymes for a more sustainable and efficient future,” said Peyman Salehian, Chief Executive Officer and Co-founder of Allozymes.

Allozymes is a biotechnology company that applies its proprietary ultra-high-throughput platform technology to rapidly develop novel enzymes and unlock the bioeconomy across diverse sectors.

Leveraging this ultra-high screening power, the firm aims to build the largest enzyme data library in the world to address the current and future needs of building robust biosolutions.

The firm’s core technology lies in its proprietary microfluidic platform, which boasts the industry’s fastest enzyme screening capability, analyzing over 20 million variants per day.

This translates to a 200 times higher chance of success in developing custom enzymes with precise properties for specific industrial applications.

Beyond ultra-high-throughput screening, Allozymes differentiates itself through its advanced enzyme sorting and detection capabilities.

This allows the company to not only identify promising enzyme candidates but also precisely match them to specific industrial needs, addressing a critical bottleneck in traditional enzyme discovery methods.

“Our platform represents a significant step forward in democratizing access to powerful enzymatic solutions,

“By providing a centralized platform for enzyme discovery and engineering, we aim to empower researchers and companies of all sizes to harness the potential of enzymes and accelerate innovation across various industries,” said Akbar Vahidi, Chief Technology Officer of Allozymes.

With this strategic investment and a dedicated team, Allozymes said the firm is poised to become a global leader in enzyme innovation.

It said the company’s groundbreaking technology offers a path toward a greener and more resource-conscious future by enabling sustainable and efficient industrial processes across diverse sectors.

Singapore’s NSG BioLabs raises $14.5M in financing round led by Celadon Partners